Similar articles

• Double-blind trial of equine antitoxin and human immune globulin in tetanus neonatorum.

  McCracken GH Jr, Dowell DL, Marshall FN. McCracken GH Jr, et al. Lancet. 1971 Jun 5;1(7710):1146-9. doi: 10.1016/s0140-6736(71)91659-x. Lancet. 1971. PMID: 4102858 Clinical Trial. No abstract available.
• [Clinical experiences in the use of intravenously injectable tetanus-immune human gamma globulin TIG(i). II. Clinical and side effects (author's transl)].

  Ebisawa I, Kurosu Y, Otsuka T, Matsuhashi C, Yamamoto A. Ebisawa I, et al. Kansenshogaku Zasshi. 1981 Feb;55(2):101-8. doi: 10.11150/kansenshogakuzasshi1970.55.101. Kansenshogaku Zasshi. 1981. PMID: 6167648 Japanese. No abstract available.
• [Therapeutic consequences of immunologic reactions in manifest tetanus].

  Hiotakis K, Feischl P. Hiotakis K, et al. Munch Med Wochenschr. 1971 Nov 19;113(47):1591-5. Munch Med Wochenschr. 1971. PMID: 4109151 German. No abstract available.
• Intrathecal vs. intramuscular administration of human antitetanus immunoglobulin or equine tetanus antitoxin in the treatment of tetanus: a meta-analysis.

  Kabura L, Ilibagiza D, Menten J, Van den Ende J. Kabura L, et al. Trop Med Int Health. 2006 Jul;11(7):1075-81. doi: 10.1111/j.1365-3156.2006.01659.x. Trop Med Int Health. 2006. PMID: 16827708 Review.
• [Current directions in the treatment of tetanus].

  Leonardi G. Leonardi G. Recenti Prog Med. 1975 Jan;58(1):75-131. Recenti Prog Med. 1975. PMID: 778948 Review. Italian. No abstract available.